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Abstract
Background: The most common form of malaria outside Africa, Plasmodium vivax, is more difficult to control than P.
falciparum because of the latent liver hypnozoite stage, which causes multiple relapses and provides an infectious reservoir.
The African (A2) G6PD (glucose-6-phosphate dehydrogenase) deficiency confers partial protection against severe P.
falciparum. Recent evidence suggests that the deficiency also confers protection against P. vivax, which could explain its
wide geographical distribution in human populations. The deficiency has a potentially serious interaction with antirelapse
therapies (8-aminoquinolines such as primaquine). If the level of protection was sufficient, antirelapse therapy could
become more widely available. We therefore tested the hypothesis that G6PD deficiency is protective against vivax malaria
infection.
Methods and Findings: A case-control study design was used amongst Afghan refugees in Pakistan. The frequency of
phenotypic and genotypic G6PD deficiency in individuals with vivax malaria was compared against controls who had not
had malaria in the previous two years. Phenotypic G6PD deficiency was less common amongst cases than controls (cases: 4/
372 [1.1%] versus controls 42/743 [5.7%]; adjusted odds ratio [AOR] 0.18 [95% confidence interval (CI) 0.06–0.52], p=0.001).
Genetic analysis demonstrated that the G6PD deficiency allele identified (Mediterranean type) was associated with
protection in hemizygous deficient males (AOR=0.12 [95% CI 0.02–0.92], p=0.041). The deficiency was also protective in
females carrying the deficiency gene as heterozygotes or homozygotes (pooled AOR=0.37 [95% CI 0.15–0.94], p=0.037).
Conclusions: G6PD deficiency (Mediterranean type) conferred significant protection against vivax malaria infection in this
population whether measured by phenotype or genotype, indicating a possible evolutionary role for vivax malaria in the
selective retention of the G6PD deficiency trait in human populations. Further work is required on the genotypic protection
associated with other types of G6PD deficiency and on developing simple point-of-care technologies to detect it before
administering antirelapse therapy.
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The majority of malaria outside sub-Saharan Africa is caused by
Plasmodium vivax, which causes up to 390 million clinical cases a
year amongst a population at risk of approximately 2.6 billion
[1,2]. Its wide geographical distribution is due, in part, to its ability
to undergo development (sporogony) in mosquitoes at a lower
temperature than P. falciparum and to its formation of a latent liver
stage (the hypnozoite), which initiates secondary blood-stage
infections [3]. These characteristics make vivax malaria signifi-
cantly more difficult to control or eliminate than falciparum
malaria.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the
most common genetic enzymopathy in humans with more than
200 variants identified to date [4]. Because the trait is X-linked
and recessive, expression of phenotypic deficiency occurs more
frequently in males than females. G6PD deficiency is relatively
rare in populations where malaria is rare but may exceed 10%
in prevalence where malaria is common [5]. In patients with
G6PD deficiency, treatment with 8-aminoquinoline drugs such
as primaquine may cause methemoglinaemia [6] and precipitate
haemolytic anaemia which, although often mild and subclinical,
can be severe in some people with particular G6PD deficiency
variants [7,8]. The potentially life-threatening interaction
between the enzyme deficiency and anti-hypnozoite drugs
places a major constraint on the ability of endemic countries
to control or eliminate vivax malaria, because G6PD testing is
not available in most areas with vivax malaria, so safe treatment
of hypnozoite infections with 8-aminoquinoline drugs is not
deemed feasible [9].
The concordance of the distribution of G6PD deficiency with
maps of historical malaria led to the hypothesis that the trait is
protective against P. falciparum. This hypothesis was confirmed
in endemic areas of Africa where the African (A2)v a r i a n to f
G6PD deficiency protected against severe disease [10–12].
Falciparum malaria is now thought to be the principal
evolutionary driver for retention of the A2 variant of G6PD
deficiency [10–12]. Mediterranean and Asian variants of G6PD
deficiency are, however, more common in areas where vivax
malaria is endemic. Mediterranean variants tend to cause more
significant haemolysis than the A2 variant when challenged
with antimalarial drugs, fava beans, or other environmental
stressors. A recent study [13] demonstrated that one Asian
variant (G6PD-Mahidol) was associated with lower levels of
parasitaemia in Thai adults with vivax malaria, but not with P.
vivax infection or with P. falciparum. Genetic evidence for an
evolutionary interaction was also demonstrated. Vivax malaria,
often incorrectly assumed to be benign [14,15], seems likely to
exert evolutionary pressure for retention of the G6PD trait in
human populations. We therefore investigated whether G6PD
deficiency is protective against vivax malaria infection in a
South Asian population in Pakistan.
Methods
Using a case-control design, we examined the association of
G6PD deficiency with vivax malaria, retrospectively, over 2 years of
observation. The study was conducted in three Afghan refugee
villages in North West Frontier Province, Pakistan (Adizai,
Baghicha, and Kaghan). The refugee villages had populations
ranging from 1,000 to 3,500 people. Malaria transmission was
seasonal and hypoendemic [16,17] with the majority (approximately
95%) of cases being due to vivax malaria and the remainder to P.
falciparum. Ethnically, the population is Pashtun [18].
Selection of Cases and Controls
In November and December 2006, cases were selected from
residents of the refugee villages who in earlier studies were
diagnosed with vivax malaria [19,20]. Cases were defined as
individuals who had had at least one episode of vivax malaria in
the previous 2 years based on research slides collected using
standard methods and double read by two experienced micros-
copists. Discordant slides were read by a third microscopist. A
cross-checking procedure was in place in all clinics and maintained
accuracy at .98% [21] (HealthNet TPO, unpublished data,
2004–5). In addition, PCR was conducted on blood samples taken
from cases during one of the studies [19] (n=30), which confirmed
that all tested cases were indeed infected with P. vivax.
Villagehealthrecordswereusedtoselectcommunitycontrolsfrom
the same population as cases. Controls had no known episodes of
malaria during the same 2 years of observation. The record system
contained information on every family, and each family had a health
card onwhichevery memberwas recordedby name. Theregistration
was regularly updated for births and deaths during consultation in the
village health clinics. If a malaria blood smear was taken, the slide
result was recorded against the patient’s record (even if it was
negative). If the patient was parasitaemic, the treatment given was
also recorded. The records are maintained by trained village health
workers and clinic staff. This allowed the compilation of a list of all
individuals in the villages who had not had malaria over the 2 years
before the study. All residents from the same villages as cases who
were more than 2 years old and had no history of malaria in their
clinic record were therefore eligible for enrolment as controls.
Controls were selected at random from the complete list of
eligible village residents. A bottle was spun outside the house of
each case in order to select a random house and if it contained an
eligible control (of the same sex and within 5 years of age of the
case), then the control was enrolled. If no suitable control was
available, the bottle was re-spun until a suitable control was found
from a house in the vicinity of the case. The selection was therefore
controlled for the likely confounding factors of age and village
(associated with risk of infection) and sex (associated with risk of
G6PD deficiency) to ensure that disease and exposure risk was
broadly similar between cases and controls. Once informed
consent was given, the control was assessed by microscopy for
current malaria parasitaemia, and if positive the control was not
included. Because no controls had parasitaemia at the time of the
survey, none were excluded on the basis of this criterion.
Information on treatment-seeking practice was collected to identify
those individuals who had sought medical care outside the village
in the last 2 years; a restricted analysis, in which such individuals
were excluded, was conducted as a check against potential bias
resulting from malaria that was not recorded in clinic records.
Children under the age of 2 years were excluded since they would
not have been born at the start of the observation period.
Blood samples were collected in EDTA tubes and immediately
tested for phenotypic G6PD deficiency using a colorimetric test
(Sigma Diagnostics, Poole, Dorset, UK) according to the manufac-
turer’s instructions. Samples found to be deficient were tested a
second time. Each participant gave a blood sample stored on filter
paper for genetic analysis. The filter papers were allowed to dry,
marked with the participant’s identifier and stored in individual bags.
The samples selected for analysis were sent to the Department of
Genome Sciences at the University of Washington, Seattle, USA.
Ethics Statement
Ethical approval was obtained from the London School of
Hygiene and Tropical Medicine Ethics Review Board and from
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All participants gave written informed consent to participate. For
the gene sequencing, ethical approval was given by the University
of Washington Ethics Committee.
Statistical Analysis
The primary analysis examined the association between
phenotypic G6PD deficiency and vivax malaria. A sample size
was calculated for a 2:1 ratio of controls to cases. A sample of 500
cases and 1,000 controls gave 80% power to detect a frequency of
phenotypic G6PD deficiency of 1% amongst cases and 3.5%
amongst controls [19,20] at the 95% confidence level.
We conducted univariate and multivariate analysis using
unconditional logistic regression and adjusting for prespecified
potential confounding factors between cases and controls; those
factors included in the final unconditional multivariate logistic
regression model for the primary outcome were age group, sex,
tribe, and refugee village. In response to suggestions from the
statistical referee we undertook an additional post-hoc analysis
using conditional logistic regression, which was not part of the
prespecified analytical plan. In this analysis each case was matched
with the two controls identified in their village by bottle-spinning
and was thus matched for village, sex, and age group. We included
tribe as a potential confounding factor in the model.
G6PD deficiency is an X-linked mutation so the secondary
analysis examined the association between the deficiency (both
phenotypic and genotypic) and infection separately for males and
females. This analysis took the same approach as before and
applied unconditional logistic regression and a post-hoc condi-
tional logistic regression. The genotyped samples were used to
assess the level of protection conferred by confirmed hemizygous
deficiency in males and heterozygous and homozygous deficiency
in females. The study was not powered specifically for the
secondary analyses. Data was analysed using STATA v8 (STATA
Corp, College Station, TX, USA).
Genetic Analysis
Participant blood samples were examined for G6PD genotype
in two phases. Initially, we selected half of the samples from males
who were phenotypically deficient and the requisite number of
male non-deficient samples (in an approximate 1:2 ratio). We then
amplified a 5.2 kb fragment using the primers 13125F: 59 GTT
TAT GTC TTC TGG GTC AGG GAT GG 39 and 18396R: 59
AGT GTT GCT GGA AGT CAT CTT GGG T 39 from
Saunders et al, [22]. Forty-six out of 57 of the samples that we
attempted to amplify gave good sequence across the majority of
that fragment (up to exon 10) and showed that the predominant
allele was the Mediterranean (Med) type.
In the second phase we conducted PCR amplification of Med
allele fragments on the 40% sample of the participants whose
samples were available, in equal proportion between cases and
controls. These comprised the same 1:2 ratio of cases to controls
and allowed examination of the frequency of the Med2 allele
between cases and controls. Med allele fragments were amplified
in a 20 ml reaction volume containing: 16PCR PreMix A, 0.2 mM
each primer, 0.5 units FailSafe enzyme mix (Epicentre, Madison,
WI), and 2 mL of template DNA. Cycling conditions were: 94uC
for 3 min; 36 cycles of 94uC for 30 s, 55uC for 30 s, 62uC for 60 s;
62uC for 5 min, 15uC for 5 min. Sequencing was done in a 10 ml
volume, using 1–3 ml of PCR product, 1.7 ml5 6sequencing buffer
for Big Dye (400 mM Tris-HCl, 10 mM MgCl2, pH=9.0),
0.8 mM primer, and 1 ml Big Dye (Applied Biosystems, Foster
City, CA). Products of sequencing reactions were separated on an
ABI 3130xl (Applied Biosystems, Foster City, CA) and analyzed
using Sequencher (Gene Codes Corporation, Ann Arbor, MI).
The following primers were used for the Med allele: Medf: 59
ATGATGCAGCTGTGATCCTCACTC 39 and Medr: 59 AT-
GAGGTTCTGCACCATCTCCTTG 39.
Results
A total of 372 cases and 743 controls were enrolled into the
study at a ratio of roughly 1:2. Table 1 shows enrolment data for
cases and controls. There were no differences in the frequency of
sex, village, or age group between cases and controls, although
tribal group did differ. There was a lower than anticipated number
of participants, because some of the cases (identified in the earlier
studies [19,20]; n=125) had either repatriated to Afghanistan or
had been enrolled more than once in the previous studies (but
were included only once in the present survey). All participants
were ethnic Pashtuns.
There was a lower frequency of phenotypic G6PD deficiency
amongst cases (4/372 [1.1%]) than controls (42/743 [5.7%]),
Chi
2=13.1, p,0.001) (Table 2). Unconditional univariate analysis
was conducted to identify prespecified potential confounding
associations with G6PD deficiency. The prespecified variables
entered into the unconditional logistic regression model were sex,
age group, refugee village, and tribe (Table 2). The primary
analysis demonstrated significant protection in those with
phenotypic G6PD deficiency with adjusted odds ratio (AOR)
0.18 [95%CI 0.06–0.52], p=0.001. Overall, tribe was associated
with the deficiency, and there was some variation between
individual tribal groups (Table 2). For the post-hoc matched
analysis, the AOR (0.17 [95% CI 0.06–0.48], p=0.001) was
similar to the unmatched analysis (Table 2) although the
association with tribe was not seen.
Because the G6PD gene is located on the X chromosome, sex-
stratified analysis was also conducted. The frequency of deficiency
Table 1. Characteristics of cases and controls.
Variable Cases (n=372) Controls (n=743)
Mean age (y) 13.6 13.5
Age group, n (%)
a
2–10 213 (57.2) 395 (53.4)
11–20 104 (28.0) 237 (32.0)
.20 55 (14.8) 108 (14.6)
Sex, % male 42.2 42.7
Ethnic group (Pashtun, %) 100 100
Tribe, n (%)
b
Safi 167 (44.9) 346 (46.4)
Mamund 39 (10.5) 126 (17.0)
Shinwari 29 (7.8) 47 (6.3)
Tarakheil 23 (6.2) 32 (4.3)
Unknown 67 (18.0) 175 (23.5)
Other 47 (12.6) 17 (2.3)
Refugee village, n (%)
Adizai 288 (77.4) 575 (77.4)
Baghicha 65 (17.5) 130 (17.5)
Kaghan 19 (5.1) 38 (5.1)
aData missing from four controls.
bChi
2=59.5, p,0.001.
doi:10.1371/journal.pmed.1000283.t001
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males, G6PD deficiency was less likely in cases than in controls
(AOR 0.12 [95%CI 0.03–0.49], p=0.004). Amongst females we
did not detect evidence of an effect (AOR 0.35 [95%CI 0.08–
1.61], p=0.2), the number of deficient females being too low to
make a robust estimate (n=2/215) (Table 3). For the post-hoc
matched analysis, the AOR was again similar between the
unmatched analysis (Table 3) and the matched analysis (AOR
from matched analysis, amongst males: 0.11 [95% CI 0.03–0.51],
p=0.004 and amongst females: 0.35 [95% CI 0.07–1.67, p=0.19).
A total of 418 samples were successfully sequenced to provide
genotype data (Table 4). As expected, all of the hemizygous
G6PD-deficient males (n=16) and homozygous deficient females
(n=2) in the sample were phenotypically deficient, and all
genotypically G6PD normal males and females were phenotypi-
cally nondeficient. Of the heterozygous females 24/32 (75%) were
phenotypically normal and 25% were phenotypically deficient. All
individuals identified as carrying the mutant allele had a C to T
change at nucleotide 563, which is characteristic of the
Mediterranean variant and similar to alleles found in India [23]
and Iran [24]. Six samples (three male and three female) yielded
discordant results showing phenotypic deficiency but a normal
genotype. All of these were controls (Table 4). Attempts to
examine other possible variants (Orissa, Chatham, and Cosenza)
were unsuccessful.
The secondary analysis, conducted using G6PD genotype as the
explanatory variable, showed that females carrying a single or
double copy of the deficiency were partially protected against
vivax malaria infection (pooled AOR: 0.37 [95% CI 0.15–0.94],
p=0.037) (Table 5). Amongst heterozygous females, there was
weak evidence of protection although the sample size was small for
this analysis (Table 5). Only three homozygous deficient females
Table 2. Effect of malaria, sex, age group, village, and tribe on frequency of phenotypic G6PD.
Variable G6PD Deficient, n/N (%) Odds Ratio (95% CI) P value Adjusted Odds Ratio (95% CI) P Value
Malaria history
Control 42/743 (5.7) 1 1
Case 4/372 (1.1) 0.18 (0.06–0.51) 0.001 0.18 (0.06–0.52) 0.001
Sex
Male 33/473 (7.0) 1 1
Female 13/641 (2.0) 0.28 (0.14–0.53) ,0.001 0.30 (0.15–0.59) 0.001
Age group (y) 0.59 0.93
2–10 26/608 (4.3) 1 1
11–20 15/341 (4.4) 1.03 (0.54–1.97) 0.9 0.93 (0.46–1.86) 0.8
.20 5/163 (3.1) 0.71 (0.27–1.87) 0.5 0.95 (0.33–2.71) 0.9
Refugee village 0.03 0.004
Adizai 27/863 (3.1) 1 1
Baghicha 14/195 (7.2) 2.39 (1.23–4.66) 0.01 2.48 (1.01–6.04) 0.046
Kaghan 5/57 (8.8) 2.98 (1.10–8.04) 0.03 3.05 (0.98–9.46) 0.054
Tribe 0.02 0.007
Safi 25/513 (4.8) 1 1
Mamund 7/165 (4.2) 0.86 (0.37–2.04) 0.7 0.57 (0.23–1.45) 0.2
Shinwari 8/76 (10.5) 2.30 (1.00–5.30) 0.051 0.93 (0.31–2.82) 0.9
Tarakheil 2/55 (3.6) 0.74 (0.17–3.20) 0.7 1.04 (0.23–4.69) 1.0
Unknown 4/242 (1.7) 0.33 (0.11–0.95) 0.04 0.22 (0.07–0.67) 0.008
Other 0/64 — — — —
doi:10.1371/journal.pmed.1000283.t002
Table 3. Unadjusted ORs and AORs for phenotypic G6PD deficiency stratified by sex.
n/N (%) OR (95% CI) p-Value AOR
a (95% CI) p-Value
Males
Control 31/316 (9.8) 1 1
Case 2/157 (1.3) 0.12 (0.03–0.50) 0.004 0.12 (0.03–0.49) 0.004
Females
Control 11/426 (2.6) 1 1
Case 2/215 (0.9) 0.35 (0.08–1.61) 0.2 0.35 (0.08–1.61) 0.2
aOdds ratios adjusted for village (unpublished data); age group and tribe were dropped due to no univariate effect (age group) or low sample sizes (tribe).
doi:10.1371/journal.pmed.1000283.t003
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males the AOR was 0.12 (95% CI 0.02–0.92), p=0.041.
The frequency of the allele for G6PD deficiency among male
controls was 12.1% (15/124), and because males carry a single
copy of the X-linked gene, this approximates the population
frequency of the deficient allele (Table 5). Among the female
controls, there were 16.9% (26/154) heterozygotes and 1.3% (2/
154) homozygotes for G6PD deficiency. Therefore, if the
frequency of the allele among controls approximates the
population genotype frequencies, more than 90% (26/28) of
G6PD deficiency alleles in females occur as heterozygotes and only
7.4% (2/28) as homozygotes; this is similar to the genotype
frequencies in females predicted by the Hardy-Weinberg model
(i.e., 1.5% homozygotes for deficiency, 21.3% heterozygotes,
77.3% G6PD normal) based on a G6PD deficient allele frequency
of 12.1% (Chi
2=1.03, p=0.69). Among cases, the frequency of
the allele among males (1.6%) and females (7.7%) was much lower,
and being protective against malaria these will differ from the gene
frequency in the general population.
To examine evidence of possible misclassification of cases as
controls, several factors that could have led to misclassification
were considered using a restricted analysis against the primary
outcome, as follows. Less than one-third of the controls reported
using health facilities outside the village as their source of
consultation for minor illness or malaria treatment and diagnosis
(30.0%, 13.2%, respectively). Also amongst controls, 26/743
(3.5%) had self-reported malaria, which was not recorded in clinic
records over the period of observation and 5/743 (0.7%) had
ambiguous clinic records. In addition, 202/727 (27.8%) of controls
were family members of cases. The restricted analysis, in which all
individuals who were in these categories were excluded, produced
results that did not differ from the unrestricted analysis.
Discussion
The study demonstrated that G6PD deficiency, whether
measured by phenotype or genotype, is associated with substantial
protection against vivax malaria infection. Among heterozygous
females the deficiency was associated with protection less often
than in hemizygous males. In populations where G6PD deficiency
has been measured it rarely occurs at a frequency greater than
15% [4,5,9,11]. Even at this upper limit of the frequency range,
the majority of phenotypically G6PD deficient females will be
heterozygous. Heterozygous females may be either phenotypically
deficient or normal depending on the relative proportion of
circulating deficient and nondeficient red cells, because females
exhibit mosaicism in expression of G6PD [25]. In our sample,
75% of heterozygous females were phenotypically normal, despite
which there was a trend towards protection in this group.
The discovery that G6PD deficiency is protective against P. vivax
infection is supported by its geographical distribution and may
explain why the more severe variants (Mediterranean and Asia)
are seen in vivax-predominant areas. This study is supported by
recently published findings [13] that the G6PD Mahidol
deficiency, an Asian strain, is associated with reduced parasitaemia
and had experienced strong selection pressure from about 2,500
years ago. We have demonstrated a stronger protection against
infection by the Mediterranean variant. The relationship between
the type of G6PD variant and level of protection requires further
investigation but the contrary findings presented here and in
Thailand suggest that it differs between variants. Too few cases
had G6PD deficiency in our sample to reliably analyse its effect on
parasite density amongst cases.
Malaria is considered by some to be the single greatest source of
selection pressure acting on human populations originating from
endemic areas [12,26], and the geographical distribution of several
genetic polymorphisms that are protective against malaria are
consistent with this theory [26,27]. The finding that G6PD
deficiency is protective against severe P. falciparum malaria in
African variant G6PD-deficient children [10–12] is one example
of this evolutionary interaction. Our findings provide strong
empirical evidence, and complement the evolutionary genetic
Table 4. Sample description for genotyped samples.
Controls n/N (%) Cases n/N (%)
Genotyped 298/743 (40.1) 150/372 (40.3)
Yielding sequence 278/298 (93.3) 140/150 (93.3)
Discordant (males)
a 3/124 (2.4) 0/62
Discordant (female)
a 3/154 (2.0) 0/78
aDiscordant: Phenotype deficient, but with wild type for the Med- allele. The
three discordant females were all homozygous WT against the Med allele assay.
doi:10.1371/journal.pmed.1000283.t004
Table 5. Frequency of G6PD deficiency genotype between cases and controls.
Control n/N (%) Case n/N (%) Univariate Multivariate
a
OR (95% CI) p- Value OR (95% CI) p-Value
Males
G6PD normal
b 109 (87.8) 61 (98.4) 1 1
Hemizygous deficient 15 (12.1) 1 (1.6) 0.12 (0.02–0.92) 0.042 0.12 (0.02–0.92) 0.041
Females
Homozygous Normal 126 (81.8) 72 (92.2) 1 1
Heterozygous 26 (16.9) 6 (7.7) 0.40 (0.16–1.03) 0.057 0.40 (0.16–1.02) 0.055
Homozygous deficient 2 (1.3) 0 — —
Heterozygous and homozygous 28 (18.2) 6 (7.7) 0.38 (0.15–0.95) 0.038 0.37 (0.15–0.94) 0.037
aOdds ratios adjusted for village (unpublished data); age group and tribe dropped due to nonsignificance (age group) and low sample sizes (tribe).
bBoth wild-type and Med variant alleles shared the same basic B allele background as found in GenBank accession no. L44140 and cited in Saunders et al. [22], but we
identified three indels, within introns at positions, 584.1, 628.1, and 1450.1 (numbering based on Saunders 5.2 kb fragment). The only difference between the Med
variant and wild-type alleles was the single nucleotide change at nt 563.
doi:10.1371/journal.pmed.1000283.t005
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considerable selection pressure on human populations. This
pressure could come either through mortality—severe vivax
malaria being much more common than previously realised
[14,15]—or through an indirect socioeconomic effect on human
fecundity [2,27]. P. vivax is known to cause anaemia and low
birthweight in pregnancy [28] and the effect of malaria in young
children can lead to mental and physical retardation [2]. A recent
evaluation of the clinical picture of vivax malaria has identified
complications which had not been previously acknowledged as
common, for example, severe anaemia, cerebral malaria, renal
failure, hepatic dysfunction, acute respiratory distress syndrome,
sepsis and shock [14,15]. Most areas outside Africa that are
endemic for vivax malaria also have falciparum malaria. Recent
data describing the relative proportion of the two species is
inconsistent with evolutionary time, and drawing conclusions as to
the relative impact of these species on human evolution and the
retention of the G6PD gene in coendemic areas requires caution.
However, vivax malaria is thought to have originated in Asia [29]
and to have existed for longer than falciparum [30,31].
Furthermore, vivax malaria is known to have been endemic to
Africa before the emergence between 30,000 and 10,000 years ago
of the Duffy negative trait which confers almost complete
immunity to P. vivax [27], providing indirect evidence that vivax
has exerted evolutionary pressure on human populations. Vivax
could certainly have contributed to the retention of the deficiency.
The discovered protection is biologically plausible. G6PD-
deficient erythrocytes infected by P. falciparum are known to be
more sensitive to the oxidative stress produced by the parasite [4].
The resulting cellular damage impairs parasite growth, causes lysis
of infected cells, and stimulates early phagocytosis of erythrocytes.
This is likely to be as relevant in vivax as falciparum malaria. Lysis
of G6PD-deficient red cells challenged with oxidative stress is, in
part, dependent on the age of the cell. The African deficiency
variant generally causes significant lysis only in older erythrocytes,
but the Mediterranean variant also causes damage and ultimately
lysis of young erythrocytes (reticulocytes) in the presence of a
variety of stressors such as drugs or infection. Vivax malaria
preferentially infects reticulocytes whilst falciparum malaria infects
erythrocytes of all ages [26]. The Mediterranean variant G6PD
deficiency is one of the most common of the severe deficiencies
and has potential adverse negative selective effects (such as favism).
Its wide distribution across Asia may be explained if it confers
greater protection against vivax than against falciparum malaria.
Potential shortcomings of the case-control design include
misclassification of cases as controls at the selection stage.
Misclassification will be limited because asymptomatic infections
are rare (none were found in this study) and almost all treatment
was given in village clinics. Any such misclassification is unlikely to
explain the observed result because any dilution would underes-
timate the effect of G6PD deficiency on vivax infection. Similarly,
misclassification due to patients with P. falciparum being wrongly
diagnosed as having P. vivax is unlikely in the present study because
the highly trained research microscopists were routinely subjected
to quality control through slide re-examination [21]; secondly, all
slides were double-read (or triple-read); thirdly, PCR was
conducted on 30 samples from cases which confirmed the
microscopic diagnosis; fourthly falciparum malaria, at the time
of the study, was very rare in this area.
G6PD deficiency is heritable and therefore could be clustered at
the household level and provide a source of sampling bias.
However, when family members of cases were excluded from the
analysis, the overall conclusions were unchanged; again, residual
clustering would lead to an underestimate of the observed effect.
Failure of laboratory determination of G6PD phenotypic defi-
ciency is another potential source of error. The high concordance
of genotypic and phenotypic deficiency suggests this is not a major
factor in this study. It is probable that some controls with
discordant results (i.e., normal for the Mediterranean variant but
phenotypically deficient) were, in fact genuinely G6PD deficient
for other variants that may exist at low levels in this population.
The small proportion of discordant phenotypic and genotypic
results makes this unlikely to be a significant source of bias in this
study.
In case-control studies the association between two factors does
not necessarily prove the direction of causality except in the case,
as here, of innate genetic conditions. Measured potential
confounding factors had little effect on the outcome. We conclude
that it is unlikely the apparent substantial protective effect of
G6PD deficiency arose by chance or from bias in the study design.
In public health terms, the current treatment practice in most
settings where vivax malaria is common is not to use antirelapse
therapy in proven cases of vivax malaria because of the risk of
haemolysis when testing for phenotypic G6PD deficiency is not
available. This restriction is one of the major barriers to effective
control and eventual elimination because hypnozoites constitute the
reservoir of infection. The findings presented here indicate that,
assuming accurate diagnosis, the risk of exposure to primaquine
amongst G6PD-deficient individuals with vivax malaria would be
lower than previously assumed because the prevalence of G6PD in
vivax-infected patients would be significantly lower than in the
general population. It is important to examine the level of protection
conferred by other types of G6PD variant occurring in other vivax-
endemic areas. The risk of severe haemolysis among G6PD-deficient
individuals administered with other regimens of primaquine is also
unclear; literature on this topic is sparse. For example, in
Mediterranean variant G6PD deficiency, haemolysis with prima-
quine can be severe and, on the basis of limited data, might be quite
common if full 14-day courses are taken [32] whereas weekly
primaquine for 8 weeks seems safe in Pashtun populations [20]. For
a more informed risk analysis, additional data is required, plus
modelling to assess the potential effects of G6PD variant,
epidemiological background, sex, dose, or duration of treatment
on the risk of haemolysis in deficient individuals.
Under prevailing conditions, however, G6PD testing is rarely
available and G6PD deficiency goes largely undetected, so our
finding is unlikely to increase access to antirelapse drugs in the near
future because of the continuing risk of haemolysis. Hence the
hypnozoite reservoir will remain unchallenged and will continue to
contribute to morbidity through relapse and transmission. For
effective control and treatment, either a simple test for G6PD
deficiency or an antirelapse drug that can be safely given to
patients with G6PD deficiency is required. This study, however,
shows that the probability of individuals with vivax malaria being
deficient for G6PD may be significantly lower than in the general
population from which they are drawn.
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Background. Malaria is a parasitic infection transmitted to
people through the bite of an infected mosquito. Although
Plasmodium falciparum is responsible for most malaria
deaths, P. vivax is the commonest, most widespread cause
of malaria outside sub-Saharan Africa. Like other malaria
parasites, P. vivax has a complex life cycle. Infected
mosquitoes inject a parasitic form known as sporozoites
into people where they replicate inside liver cells without
causing symptoms. About 8–9 days later, merozoites
(another parasitic form) are released from the liver cells
and invade red blood cells. Here, they replicate rapidly
before bursting out and infecting more red blood cells. This
increase in the parasitic burden causes malaria’s
characteristic symptoms (debilitating and recurring chills
and fevers). P. vivax infections are usually treated with
chloroquine (although resistance to this drug is now
emerging) but patients must also take primaquine, a drug
that kills hypnozoites, a form of P. vivax that hibernates in
the liver. Hypnozoites can cause a relapse months after the
initial bout of malaria and make P. vivax malaria harder to
control than P. faciparum malaria.
Why Was This Study Done? Some mutations (DNA
changes) protect their human carriers against specific
disease-causing organisms. These mutations occur at high
frequencies in populations where these organisms are
common. For example, the widespread distribution of
mutations that cause a deficiency in an enzyme called
glucose-6-phosphate dehydrogenase (G6PD) mirrors the
distribution of malaria and the African (A2) form of G6PD
deficiency, a type of G6PD deficiency that is common in
people of African origin, is known to provide partial
protection against severe P. falciparum malaria—P.
falciparum does not thrive in G6PD-deficient red blood
cells. In areas where P. vivax malaria is common,
Mediterranean and Asian variants of G6PD deficiency are
more widespread than A2 G6PD, so the question is, do
these variants protect against P. vivax malaria? In this case-
control study (a study in which the characteristics of people
with and without a specific condition are compared), the
researchers investigate whether G6PD deficiency protects
against P. vivax infection in a population of Afghan refugees
living in Pakistan.
What Did the Researchers Do and Find? The researchers
enrolled 372 Afghan refugees who had had P. vivax malaria
during the previous two years and 743 refugees who had not
had malaria over the same period. They measured G6PD
activity in the participants’ blood to detect ‘‘phenotypic’’
G6PD deficiency (reduced enzyme activity) and looked for
the Mediterranean variant of the G6PD gene in the
participants (‘‘genotypic’’ G6PD deficiency). 5.7% of the
controls but only 1.1% of the cases had phenotypic G6PD
deficiency. Statistical analyses indicated that participants
with reduced G6PD levels were about one-fifth as likely to
develop P. vivax malaria as those with normal G6PD levels
after allowing for other factors that might affect their
susceptibility to malaria, an adjusted odds ratio (AOR) of
0.18. The genetic analysis indicated that the Mediterranean
G6PD gene variant provided protection against P. vivax
infection in men (AOR 0.12) and in women carrying either
one or two defective copies of the G6PD gene (AOR 0.37);
because the G6PD gene is on the X chromosome, men have
only one copy of the gene but women have two copies.
What Do These Findings Mean? These findings indicate
that Mediterranean-type G6PD deficiency protects against P.
vivax malaria infection in this population of Afghan refugees.
Although further studies are needed to determine whether
other G6PD variants protect against P. vivax malaria, these
findings suggest that P. vivax malaria might be responsible
for the retention of the G6PD deficiency trait in some human
populations. In addition, these findings may have
implications for the treatment of P. vivax malaria. Currently,
in most places where P. vivax malaria is common, primaquine
is not given routinely because primaquine can trigger red
blood cell death (hemolytic anemia) in G6PD-deficient
people and tests for G6PD deficiency are rarely available.
These findings suggest that the risk of exposure to
primaquine among people infected with P. vivax might be
lower than previously assumed, because G6PD deficiency is
less common among P. vivax-infected patients than among
the general population. Nevertheless, these findings are
unlikely to increase the use of primaquine immediately. Such
an increase, the researchers suggest, will only occur if a
simple test for G6PD deficiency is developed.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000283.
N Information is available from the World Health Organiza-
tion on malaria (in several languages)
N The US Centers for Disease Control and Prevention
provides information on malaria (in English and Spanish)
N Information is available from the Wellcome Trust on all
aspects of malaria, including a news item about G6PD
deficiency protecting against severe P. falciparum malaria
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
N The Malaria Vaccine Initiative has a fact sheet on
Plasmodium vivax malaria
N Vivaxmalaria provides information about P. vivax
N More about G6PD deficiency can be found on KidsHealth
from the Nemours Children’s Health System
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